Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
Sponsor: Ironwood Pharmaceuticals, Inc.
A PHASE3 clinical study on Gastroesophageal Reflux Disease (GERD), this trial is completed. The trial is conducted by Ironwood Pharmaceuticals, Inc. and has accumulated 13 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE3
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Nov 2019 — Jun 2020 [monthly]
Recruiting PHASE3
-
Feb 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Nov 2018 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ironwood Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .